NCT02506192View on ClinicalTrials.gov

Gulf War Illness Inflammation Reduction Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

October 19, 2023

Study Completion Date

October 19, 2023

Conditions
Chronic InflammationChronic PainFatigueCognitive Impairment
Interventions
DRUG

Modified-Release Prednisone

Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks

DRUG

Placebo

Placebo oral tablets (2x5mg) daily for 8 weeks

Trial Locations (1)

55417

Minneapolis Veterans Affairs Medical Center, Minneapolis

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Minneapolis Veterans Affairs Medical Center

FED

NCT02506192 - Gulf War Illness Inflammation Reduction Trial | Biotech Hunter | Biotech Hunter